+

WO2010063030A2 - Application dermique de vasoconstricteurs - Google Patents

Application dermique de vasoconstricteurs Download PDF

Info

Publication number
WO2010063030A2
WO2010063030A2 PCT/US2009/066124 US2009066124W WO2010063030A2 WO 2010063030 A2 WO2010063030 A2 WO 2010063030A2 US 2009066124 W US2009066124 W US 2009066124W WO 2010063030 A2 WO2010063030 A2 WO 2010063030A2
Authority
WO
WIPO (PCT)
Prior art keywords
vasoconstrictor
pharmaceutical composition
skin
patient
kit according
Prior art date
Application number
PCT/US2009/066124
Other languages
English (en)
Other versions
WO2010063030A3 (fr
Inventor
Oron Zachar
Original Assignee
Feigelson, Daniel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2009/000652 external-priority patent/WO2010001391A1/fr
Application filed by Feigelson, Daniel filed Critical Feigelson, Daniel
Priority to EP09829849A priority Critical patent/EP2376073A2/fr
Priority to CN2009801558027A priority patent/CN102300566A/zh
Publication of WO2010063030A2 publication Critical patent/WO2010063030A2/fr
Priority to US12/982,117 priority patent/US20110144209A1/en
Publication of WO2010063030A3 publication Critical patent/WO2010063030A3/fr
Priority to US13/118,563 priority patent/US20120095104A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • hypothermia a core body temperature (CBT) ranging between 96.8°F and 100.4 0 F (36°C and 38°C), hyperthermia as a CBT greater than 38°C, and hypothermia as a core temperature lower than 96.8°F (36°C).
  • CBT core body temperature
  • hyperthermia a CBT greater than 38°C
  • hypothermia a core temperature lower than 96.8°F (36°C).
  • Unplanned hypothermia is frequently a problem during or following surgery in which the patient has been administered a general anesthetic.
  • Anesthetic-induced impairment of thermoregulatory control is the primary cause of postoperative hypothermia.
  • Evidence is that the hypothermia starts to develop already during the surgical procedure after the start of administration of anesthesia (Good et al., Association of Operating Room Nurses AORN Journal, May 2006, 83:5, Health Module p.1055).
  • hypothermia has been associated with a number of adverse consequences, including: increased risk of intra- operative blood loss; increased susceptibility to infection (such as myocardial ischemia); impaired coagulation and increased transfusion requirements; cardiovascular stress and cardiac complications; altered drug metabolism; postanesthetic shivering and thermal discomfort, as well as longer patient stays in the postanesthesia care unit (PACU) (Good et al., AORN Journal, May 2006; 83, 5; Health Module p. 1055).
  • PACU postanesthesia care unit
  • the heating devices used to treat or prevent anesthetic-induced hypothermia are necessarily designed to allow access to those portions of the patient body undergoing surgery. [0006] Hence, it would be useful if there existed a method to treat or prevent anesthetic-induced hypothermia, which does not involve external devices which may be expensive and/or disturbing to the surgical team.
  • a method for treating, preventing or delaying the onset of anesthetic hypothermia which comprises applying to the skin of a patient who is under general anesthetic or is about to be put under general anesthetic an amount of at least one vasoconstrictor effective to treat, prevent or delay the onset of anesthetic hypothermia.
  • the at least one vasoconstrictor is present as a mixture of vasoconstrictors.
  • the vasoconstrictor or mixture of vasoconstrictors is present in a pharmaceutical composition.
  • the pharmaceutical composition is applied to at least 10% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 15% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 20% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 25% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 30% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 35% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 40% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 45% of the patient's skin. In some embodiments, the pharmaceutical composition is applied to at least 50% of the patient's skin.
  • the skin to which the at least one vasoconstrictor is applied includes skin selected from the group consisting of the palm of the hand, the sole of the foot, the ear, and the face.
  • the at least one vasoconstrictor is applied in the form of a dermally administrable pharmaceutical composition containing at least 1% by weight of the at least one vasoconstrictor.
  • the composition contains at least 2% by weight of the at least one vasoconstrictor.
  • the composition contains at least 3% by weight of the at least one vasoconstrictor.
  • the composition contains at least 4% by weight of the at least one vasoconstrictor.
  • the composition contains at least 5% by weight of the at least one vasoconstrictor. In some embodiments, the composition contains at least 10% by weight of the at least one vasoconstrictor. In some embodiments, the composition contains at least 20% by weight of the at least one vasoconstrictor. In some embodiments, the composition contains at least 25% by weight of the at least one vasoconstrictor. In some embodiments, the composition contains at least 30% by weight of the at least one vasoconstrictor.
  • At least two vasoconstrictors are used, each of the at least two vasoconstrictors having peak effectiveness at different times after administration. In some embodiments, at least two vasoconstrictors are used, each of the at least two vasoconstrictors exerting its vasoconstrictive effect via a different mechanism. In some embodiments, at least two vasoconstrictors are used, each of the at least two vasoconstrictors having a different duration of effectiveness after administration.
  • At least one vasoconstrictor is selected from the group consisting of (i) the group consisting of vasoactive agonists, vasopressor agents and vasoconstrictor drugs; (ii) an agent that acts on vasopressin receptors or adrenoreceptors; (iii) a calcium channel agonist; (iv) an agonist of the ⁇ i adrenergic receptor; (v) alfuzosin, doxazosin, epinephrine, methoxamine, naphazoline, norepinephrine, phenylephrine, prazosin, terazosin, tetrahydrozaline, tamsulosin; (vi) an agonist of the 5HT 1 B A D receptor; (vii) almotriptan, avitriptan, frovatriptan, oxidesumitriptan, rizatriptan, zolmitriptan; (viii
  • the at least one vasoconstrictor is selected from the group consisting of methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, metaraminol, 4-(l-naphthalen-l-ylethyl)-lH-imidazole (4-NEMD), clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, methyldopa, apraclonidine, brimonidine, detomidine, dexmedetomidine, lofexidine, romifidine, tizanidine, xylometazoline, amidephrine, amitraz, anisodamine, ergotamine, indanidine, medetomidine, mephentermine, midodrine, mivazerol, naphazoline, norfenefrine, octopamine,
  • the at least one vasoconstrictor is selected from the group consisting of Ci 1 agonists and ⁇ 2 blockers. In some embodiments, the at least one vasoconstrictor is selected from the group consisting of epinephrine, norepinephrine, and pharmaceutically acceptable salts thereof.
  • the at least one vasoconstrictor is applied in the form of a dermally administrable pharmaceutical composition that further comprises at least one of an antiseptic, antibiotic, antimycotic, or antiviral compound. In some embodiments, the at least one vasoconstrictor is applied in the form of a dermally administrable pharmaceutical composition that further comprises a penetration enhancer.
  • the at least one vasoconstrictor is applied in a concentration and to an amount of skin effective to raise the patient's core body temperature by 1°C within a period of 60 minutes from administration. In some embodiments, the at least one vasoconstrictor is applied in a concentration and to an amount of skin effective to raise the patient's core body temperature by at least 1°C for a period of at least 1 hour. In some embodiments, the at least one vasoconstrictor is applied in conjunction with at least one of (a) a penetration enhancer, (b) heat from an external source, and (c) a thermogenic substance. In some embodiments, one vasoconstrictor is used. In some embodiments, more than one vasoconstrictor is used.
  • a mixture of vasoconstrictors is used.
  • a kit comprising at least one vasoconstrictor and instructions or a label explaining how to use the at least one vasoconstrictor to treat, prevent or delay the onset of anesthetic hypothermia in a patient.
  • the instructions or label instruct the user to apply the at least one vasoconstrictor to the skin of a patient who is under general anesthetic or is about to be put under general anesthetic in an amount effective to treat, prevent or delay the onset of anesthetic hypothermia.
  • the vasoconstrictor is present in a pharmaceutical composition.
  • the instructions or label instruct the user how to prepare a dermally administrable pharmaceutical composition containing the at least one vasoconstrictor.
  • the dermally administrable pharmaceutical composition contains at least 1% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 2% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 3% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 4% by weight of the at least one vasoconstrictor.
  • the dermally administrable pharmaceutical composition contains at least 5% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 10% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 15% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 20% by weight of the at least one vasoconstrictor. In some embodiments, the dermally administrable pharmaceutical composition contains at least 25% by weight of the at least one vasoconstrictor.
  • the dermally administrable pharmaceutical composition contains at least 30% by weight of the at least one vasoconstrictor.
  • the instructions or label instruct the user and to apply the pharmaceutical composition to at least 10% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 15% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 20% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 25% of the patient's skin. In some embodiments, the instructions or label instruct the user to apply the pharmaceutical composition to at least 30% of the patient's skin.
  • the instructions or label instruct the user and to apply the pharmaceutical composition to at least 35% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 40% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 45% of the patient's skin. In some embodiments, the instructions or label instruct the user and to apply the pharmaceutical composition to at least 50% of the patient's skin. In some embodiments, the instructions or label instruct that the skin to which the vasoconstrictor is applied includes skin selected from the group consisting of the palm of the hand, the sole of the foot, the ear, and the face.
  • the composition further comprises a substance selected from the group consisting of a penetration enhancer, an antiseptic compound, an antibiotic compoud, an antimycotic compound, and an antiviral compound.
  • the kit comprises at least two vasoconstrictors, each of the at least two vasoconstrictors having peak effectiveness at different times after administration. In some embodiments, the kit comprises at least two vasoconstrictors, wherein each of the at least two vasoconstrictors exerts its vasoconstrictive effect via a different mechanism. In some embodiments, the kit comprises at least two vasoconstrictors, each of the at least two vasoconstrictors having a different duration of effectiveness after administration.
  • the at least one vasoconstrictor is selected from the group consisting of (i) the group consisting of vasoactive agonists, vasopressor agents and vasoconstrictor drugs; (ii) an agent that acts on vasopressin receptors or adrenoreceptors; (iii) a calcium channel agonist; (iv) an agonist of the ⁇ i adrenergic receptor; (v) alfuzosin, doxazosin, epinephrine, methoxamine, naphazoline, norepinephrine, phenylephrine, prazosin, terazosin, tetrahydrozaline, tamsulosin; (vi) an agonist of the 5HT 1 B A D receptor; (vii) almotriptan, avitriptan, frovatriptan, oxidesumitriptan, rizatriptan, zolmitriptan; (vii)
  • the at least one vasoconstrictor is selected from the group consisting of methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, metaraminol, 4-(l-naphthalen-l-ylethyl)-lH-imidazole (4-NEMD), clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, methyldopa, apraclonidine, brimonidine, detomidine, dexmedetomidine, lofexidine, romifidine, tizanidine, xylometazoline, amidephrine, amitraz, anisodamine, ergotamine, indanidine, medetomidine, mephentermine, midodrine, mivazerol, naphazoline, norfenefrine, octopamine,
  • the at least one vasoconstrictor is selected from the group consisting of Ci 1 agonists and ⁇ 2 blockers. In some embodiments, the at least one vasoconstrictor is selected from the group consisting of epinephrine, noepinephrine, and pharmaceutically acceptable salts thereof.
  • the instructions or label explain how to apply the at least one vasoconstrictor in a concentration and to an amount of skin effective to raise the patient' s core body temperature by 1°C within a period of 60 minutes.
  • the instructions or label instruct the user to apply the at least one vasoconstrictor in conjunction with the dermal application of at least one of an antiseptic, antibiotic, an antimycotic or an antiviral compound.
  • the kit further comprises at least one of an antiseptic, antibiotic, an antimycotic or an antiviral compound.
  • the label or instructions explain how to apply the at least one vasoconstrictor in conjunction with a penentration enhancer.
  • the kit further comprises a penetration enhancer.
  • the kit contains one vasoconstrictor. In some embodiments, the kit contains more than one vasoconstrictor. In some embodiments, the kit contains a mixture of vasoconstrictors.
  • a composition containing the at least one vasoconstrictor is applied to at least 10% of a patient's skin
  • the at least one vasoconstrictor is selected from a closed group of substances
  • the at least one vasoconstrictor is utilized as one of a plurality of vasoconstrictors, separately or in a mixture, only one of the vacoconstrictors in the plurality need necessarily be selected from the members of the closed group.
  • Body thermoregulation involves three primary elements: heat production due to core body functioning, heat loss mostly through the skin surface organ, and regulatory signals from the hypothalamus brain organ.
  • the different aspects and embodiments of the present invention use vasocontrictor substances to substantially reduce body heat loss to the environment through the skin.
  • Use of additional supportive or enhancing elements in accordance with some embodiments, such as stimulation of core body functions and/or suppression of hypothalamus control and/or suppression of perspiration, are discussed herein in the context of specific applications and embodiments.
  • Vasoconstrictor substances per se - i.e. compounds that cause constriction of the blood vessels - are known in the art, but have not hitherto been used or suggested to be used in accordance with the different aspects of the invention described herein.
  • PCT patent publication WO 2006/138691 discloses pharmaceutical preparations containing vasoconstrictors and the use thereof to protect cells from the toxic side- effects of radiotherapy and cancer chemotherapeutic agents.
  • Vasoconstrictor substances used in accordance with the teaching of PCT2006 are preferably agonists of the ⁇ i adrenergic receptor (preferred embodiments of which are stated to be epinephrine, phenylephrine, methoxamine, norepinephrine, tetrahydrozaline, naphazoline, prazosin, doxazosin, terazosin, alfuzosin, tamsulosin or any combination thereof) or agonists of the 5HT 1 B A D receptor (preferred embodiments of which are stated to be zolmitriptan, oxidesumitriptan, avitriptan, rizatriptan, almotriptan, frovatriptan, or any combination thereof).
  • PCT2006 further teaches dosages of preferred embodiments.
  • US Patent No. 4978332 discusses local use of vasoconstrictors to inhibit the migration of cytotoxic drugs used for chemotherapy from the site of application of the cytotoxic drugs, by altering the blood flow serving the tumor/lesion area, so as to maintain the primary effect of the cytotoxic drug at the site of application.
  • Vasoconstrictive agents are described in Medical Pharmacology (1984), C. V. Mosby,
  • US Patent Publication Number 20030216364 teaches a topical dermatological composition with improved vasoconstrictor properties.
  • PCT patent publication WO 2004/032888 teaches a shaving cream composition containing a vasoconstrictor substance for preventing bleeding from nicks and cuts that occur while shaving the face, wherein the vasoconstrictor is phenylephrine, ephinephrine, norephinephrine, ethyinorephinephrine, potassium chloride, methoxamine, oxymetazoline), chlorpheniramine, phenylpropanolamine, tetrahydrozoline, pseudoephidrine, mephenterine, metaraminol, propylhexadrine, oxymetazoline, naphalozine, or a combination thereof, or a derivative of one of these compounds which functions as a vasocontrictor.
  • the vasoconstrictor is phenylephrine, ephinephrine, norephinephrine, ethyinorephinephrine, potassium chloride, methoxamine
  • US Patent Publication Number 20070048234 teaches methods for treating acne using a vasoconstrictor in conjunction with an anti-acne agent, wherein said vasoconstrictor is selected from the group consisting of tetrahydrozoline HCl 0.05%, naphazoline HCl 0.03%, oxymetazoline HCl 0.025%, guava extract, ellagic acid, caffeine, cypress oil, witch hazel, peppermint extract, chamomile oil, and bugleweed.
  • vasoconstrictor is selected from the group consisting of: I. the group of vasoactive agonists, vasopressor agents and vasoconstrictor drugs; II. an agent that acts on vasopressin receptors or adrenoreceptors; in. a calcium channel agonist; IV. a vasoconstrictor selected from the group including ephedrine, epinephrine, phenylephrine, angiotensin and vasopressin; V.
  • vasoconstrictor selected from the group including ephedra sinica (ma huang), polygonum bistorta (bistort root), hamamelis virginiana (witch hazel), hydrastis canadensis (goldenseal), lycopus virginicus (bugleweed), aspidosperma quebracho (quebracho bianco), cytisus scoparius
  • compositions which are particularly suited for skin lightening and for diminishing the appearance of 'dark circles' under the eyes.
  • the compositions include any of several vasoconstrictors in a carrier with optionally added skin compatible ingredients.
  • Illustrative vasoconstrictive agents are: (1) sympathomimetics including the catecholamines, norepinephrine, epinephrine, isoproterenol, dopamine, and related compounds such as ephedrine and other phenylisopropylamines, phenylephrine, amphetamine, metraminol, methoxamine; (2) ergot alkaloids including lysergic acid, lysergic acid diethylamine, ergonovine, methylergonavine, methysergide, ergotamine; (3) the angiotensins; and (4) the prostaglandins.
  • Vasoconstrictive agents are described in Medical Pharmacology (1984), C. V. Mosby, Company, Chapter 15.
  • Topical corticosteroids include hydrocortisone, Cortisol, and synthetic corticosteroids such as betamethasone, fluticasone and mometasone. They are applied to the skin in the form of creams, ointments and lotions and are the mainstay of controlling flare-ups of eczema.
  • An advantage of corticosteroids in comparison to some other dermally-applied vasoconstrictors is in their multiple hours of effectiveness (about 10 hours).
  • ⁇ -adrenoceptor agonists and antagonists Another group of compounds that act as vasoconstrictors are ⁇ -adrenoceptor agonists and antagonists. Initially classified as either ⁇ or ⁇ subtype receptors, based on anatomical location and functional considerations, more recent pharmacological and molecular biological techniques have identified the heterogeneity of the ⁇ -adrenoceptors and led to the identification of numerous subtypes of each receptor, ⁇ - Adrenoceptors exist on peripheral sympathetic nerve terminals and are divided into two subtypes, Ci 1 and ⁇ 2 . (X 1 is found mostly postsynaptically, while ⁇ 2 , although typically sited presynaptically, can also occur postsynaptically.
  • (X 1 -adrenoceptors are found both in the central and peripheral nervous system. In the central nervous system they are found mostly postsynaptically and have an excitatory function. Peripherally, they are responsible for contraction and are situated on vascular and non-vascular smooth muscle. (X 1 -adrenoceptors on vascular smooth muscle are located intrasynaptically and function in response to neurotransmitter release. For non- vascular smooth muscle, they can be found on the liver, where they cause hepatic glycogenolysis and potassium release. On heart muscle they mediate a stimulatory (positive inotropic) effect. In the gastrointestinal system they cause relaxation of gastrointestinal smooth muscle and decrease salivary secretion.
  • adrenergic compounds are vast.
  • the treatment of many medical conditions can be attributed to the action of drugs acting on adrenergic receptors.
  • ⁇ -adrenoceptor ligands can be used in the treatment of hypertension.
  • Drugs such as prazosin, an (X 1 -adrenoceptor antagonist and clonidine, an ci 2 -adrenoceptor agonist, both have antihypertensive effects.
  • Ci 1 -adrenoceptor antagonists are also employed in the treatment of benign prostatic hypertrophy.
  • ⁇ -adrenoceptor agonists are used extensively as nasal decongestants in patients with allergic or vasomotor rhinitis and in acute rhinitis in patients with upper respiratory infections (Empey et al., Drugs, June 1981, 21(6):438-443). These drugs probably decrease the resistance to airflow by decreasing the volume of the nasal mucosa.
  • the receptors that mediate this effect appear to be the (X 1 - adrenoceptors, though (X 2 -adrenoceptors may be responsible for contraction of arterioles that supply the nasal mucosa. While a major limitation of therapy with nasal decongestants is that of a loss of efficacy with prolonged use, agonists that are selective for ⁇ i receptors may be less likely to induce mucosal damage (DeBernadis et al. 1987). As an ocular decongestant, to decrease swelling and redness of the eyes, ⁇ -adrenoceptor agonists are widely used in the treatment of allergic conjunctivitis, whether seasonal (hay fever) or perennial.
  • ai adrenergic receptor agonists methoxamine, methylnorepinephrine, oxymetazoline, phenylephrine, metaraminol
  • adrenergic receptor agonists 4-(l-naphthalen-l-ylethyl)-lH-imidazole (4-NEMD), clonidine, guanfacine, guanabenz, guanoxabenz, guanethidine, xylazine, methyldopa, apraclonidine, brimonidine, detomidine, dexmedetomidine, lofexidine, romifidine, tizanidine, xylometazoline, amidephrine, amitraz, anisodamine, ergotamine, indanidine, medetomidine, mephentermine, midodrine, mivazerol, naphazoline, norfenefrine, octopamine, phenylpropanolamine, rilmenidine, synephrine, talipexole, tetrahydrozoline, xylometazoline
  • ⁇ _ [ adrenergic receptor agonists: dobutamine, dopamine, denopamine, xamoterol [0038] ⁇ ? adrenergic receptor short acting agonists: sulbutamol, levosalbutamol, fenoterol, terbutaline, pirbuterol, procaterol, bitolterol, rimiterol, carbuterol, tulobuterol, reproterol, dopexamine
  • adrenergic receptor long acting agonists arformoterol, bambuterol, clenbuterol, formoterol, salmeterol, orciprenaline, metaproterenol, ritodrine, hexoprenaline, indacaterol
  • adrenergic receptor agonists amibegron, solabegron, arbutamine, befunolol, isoxsuprine, nylidrin, oxyfedrine, prenalterol, ractopamine, bromoacetylalprenololmenthane, broxaterol, cimaterol, higenamine, mabuterol, methoxyphenamine, tretoquinol, zinterol
  • Nonselective ⁇ adrenergic receptor agonists isoprenaline, isoproterenol
  • Dual ⁇ / ⁇ adrenergic receptor agonists epinephrine Ja 1+2 , ⁇ i +2 ⁇ , norepinephrine Ja 1+2 , ⁇ i ⁇ , cirazoline, etilefrine,
  • Indirect/mixed indirect presynaptic norepinephrine release amphetamine, tyramine
  • ephedrine, pseudoephedrine cocaine, allobarbital, amobarbital, aprobarbital, barbital, butobarbital, cyclobarbital, ethallobarbital, heptabarbital, hexobarbital, methohexital, pentobarbital, phenobarbital, proxibarbal, reposal, secobarbital, talbutal, thiopental, vinylbital, vinbarbital; brotizolam, cinolazepam, doxefazepam, estazolam, flunitrazepam, flurazepam, flutoprazepam, loprazolam, lormetazepam, nitrazepam, nimetazepam, midazolam,
  • vasoconstricting agents contemplated for use in accordance with embodiments of the invention include tetrahydrozoline HCl 0.05%, naphazoline HCl 0.03%, oxymetazoline HCl 0.025%, guava extract, ellagic acid, caffeine, cypress oil, hamamelis (witch hazel), peppermint extract, chamomile oil, and bugleweed.
  • the vasoconstrictor is selected from the group consisting of methoxamine, phenylephrine, 4-NEMD, clonidine, methyldopa, dobutamine, salbutamol, terbutaline, and isoprenaline.
  • a penetration enhancer is used to facilitate the penetration of vasoconstrictor into the skin.
  • Suitable skin penetration enhancers include, for example, surfactants such as sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80) and lecithin (U.S. Pat. No.
  • the 1-substituted azacycloheptan-2-ones particularly 1-n- dodecylcyclazacycloheptan-2-one
  • alcohols such as ethanol, propanol, octanol, benzyl alcohol, and the like
  • fatty acids such as lauric acid, oleic acid and valeric acid
  • fatty acid esters such as isopropyl myristate, isopropyl palmitate, methylpropionate, and ethyl oleate
  • polyols and esters thereof such as propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, and polyethylene glycol monolaurate
  • amides and other nitrogenous compounds such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, l-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenes;
  • vasoconstrictors in accordance with embodiments of this invention may be dissolved in an appropriate pharmaceutically or cosmetically acceptable solvent and applied directly to the skin.
  • the vasoconstrictors are combined with a cream or gel base, so that application of the vasoconstrictor is more easily localized and controlled.
  • Most pharmaceutically or cosmetically acceptable gel or cream bases may be used.
  • Suitable gels include, for example, cellulose-based gels, (e.g., hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), and carboxymethyl cellulose (CMC)) and acrylate copolymers.
  • Suitable cream bases include emulsions formed from a water phase of a humectant, a viscosity stabilizer and water, an oil phase of fatty acid alcohol, a semi-solid petroleum hydrocarbon and an emulsifying agent and a phase containing the vasoconstrictor of the invention dispersed in an aqueous stabilizer-buffer solution.
  • stabilizers such as are known in the art or may be developed later, may be added in accordance with embodiments of the invention.
  • Cream-based pharmaceutical formulations containing the vasoconstrictor may be contain, for example, aqueous emulsions containing a fatty acid alcohol, semi-solid petroleum hydrocarbon, 1,2- ethyleneglycol and an emulsifying agent.
  • thermogenic substance refers to a substance which increases the metabolism of the body, thereby generating heat.
  • Common natural thermogenic substances are ephedra, bitter orange, capsicum, ginger and caffeine.
  • the ECA Stack ephedrine, caffeine, aspirin
  • Substances which block ⁇ 2 adrenoreceptors, in addition to functioning as vasoconstrictors, may in some cases also act as thermogenic substances. For example, yohimbine works by blocking ⁇ 2 adrenoreceptors.
  • NE norepinephrine
  • NE norepinephrine
  • sympathomimetic such as ephedrine
  • NE When NE is released, such as in periods of stress or after taking a sympathomimetic (such as ephedrine), it stimulates both the ⁇ and ⁇ adrenoreceptors. Stimulation of the beta adrenoreceptors causes the breakdown of fat while stimulating the ⁇ 2 adrenoreceptors has the opposite effect, preventing the release of NE and lipolysis.
  • Yohimbine prevents this negative feedback mechanism, thus increasing NE release and lipolysis. There are reasons why ⁇ 2 inhibition is specifically useful.
  • thermogenic substances While the ⁇ -adrenergic system primarily controls lipolysis during periods of intense activity, during rest, which makes up most of our day, the ⁇ -adrenergic system is in control. The increase of lipolysis is tantamount to thermo genesis. Therefore, ⁇ 2 blockers in general and Yohimbine in particular, are considered thermogenic substances in the present application.
  • thermogenic substances in one context but vasoconstrictors in another context.
  • caffeine when ingested orally and absorbed into the core body blood stream, has the effect of increasing body metabolism, thereby being thermogenic, and dilating the core blood vessels.
  • caffeine when applied dermally, caffeine has the effect of constricting cutaneous blood vessels.
  • Ephedrine is an alkaloid from the leaves of Ephedra equisetina, E. sinica, and other species (family Gnetaceae), or produced synthetically; commonly used salts are ephedrine hydrochloride and ephedrine sulfate.
  • Ephedrine is an adrenergic (sympathomimetic) agent, an alpha- and beta-adrenergic agonist, that may also enhance release of norepinephrine. Its actions similar to those of epinephrine. When inhaled, it is used as a bronchodilator, mydriatic, or pressor agent. When used topically on skin, it is a vasoconstrictor.
  • Circulation through the skin serves two major functions: nutrition of the skin tissue and heat transfer. These two functions have different hemodynamic requirements. Nutrient exchange requires slow movement of blood through thin-walled, small diameter vessels with walls permeable to small molecules. Heat exchange requires the movement of large volumes of blood through vessels closely at or near a body surface.
  • vascular structures are found in the skin of mammals: 1) nutritive units consisting of arterioles, capillaries, and venules, and 2) heat- transfer units consisting of venous plexuses (dense networks of thick- walled, large-diameter venules) and arteriovenous anastomoses (AVAs; vascular communications between small arteries and the venous plexuses).
  • nutritive units consisting of arterioles, capillaries, and venules
  • heat- transfer units consisting of venous plexuses (dense networks of thick- walled, large-diameter venules) and arteriovenous anastomoses (AVAs; vascular communications between small arteries and the venous plexuses).
  • AVAs arteriovenous anastomoses
  • Nutritive vascular units are uniformly distributed throughout the skin, whereas the heat exchange units are found only in non-insulated skin regions; in humans these are the palms of the hands, the soles of the feet, the ears, and non-hairy regions of the face (Bergersen, 1993; Gemmell and Hales, 1977; Saad, 2001). Heat exchange units also exist in the footpads and tongues of dogs (Baker, 1982), ears of elephants (Phillips and Heath, 1992) and rabbits (Ootsuka et al, 2003), and tails of rodents (Heath, 1998, Johnson 2002).
  • AVAs and associated venous plexuses are found under the nail beds, the tips of the digits, the palm, and the palmar surface of the fingers. AVAs and venous plexuses are absent from the dorsal surface of the fingers and hand (Roddie, 1983).
  • the dimensions of venous plexuses determine the blood volume capacity of a heat exchange region while the AVAs control the blood flow through the venous plexuses.
  • the heat exchange- vascular units do not contribute to the nutrition of surrounding tissues, and the nutritive units are not directly active in temperature regulation.
  • the thermoregulatory vascular units enable direct heat transfer from the body core to the surrounding environment (Krauchi et al., 1999, 2000).
  • the vasoconstrictor substance is an AVA constrictor.
  • 5-HT 1BAD receptor agonists potently constrict porcine carotid arteriovenous anastomoses, and it is likely that the same is true for humans.
  • Such agonists include sumatriptan and alniditan (De Vries et al., Eur. J. Pharmacol. 1998 351:193- 201).
  • adrenergic ⁇ rstimulation with phenylephrine produced AVA constriction.
  • Adrenergic ⁇ 2 -stimulation with UK- 14304 (5-bromo-N-(4,5-dihydro-lH- imidazol-2-yl)-6-quinoxalinamine) produced constriction of the AVA, norepinephrine (a mixed (X 1 - and ci 2 -agonist) also produced AVA vasoconstriction.
  • AVAs contain a heterogeneous mixture of both Ci 1 -and ⁇ 2 -receptors, and ⁇ 2 -receptors may have a greater influence than ⁇ rreceptors on overall tone in AVA (Pollock et al., Am. J. Physiology, Heart and Circulatory Physiology, 1996, 40:5, pp. H2007).
  • the one or more vasoconstrictor substances are administered topically to the skin. This method of administration decreases systemic effects of the vasoconstrictors, limiting the constriction of interal blood vessels and concentrating the vasoconstriction near the area of application.
  • an associated kit may contain (i) sufficient quantities of vasoconstrictor substance in a form appropriate for topical application, such as a gel, cream, foam, or ointment (or powder suitable for mixture within a liquid), and/or (ii) appropriate instructions.
  • Hypothermia is defined as body temperature below 36°C.
  • treating hypothermia should be understood as raising core body from a temperature below 36°C to a temperature of at least 36°C, and preventing hypothermia should be understood as maintaining core body temperature at or above 36°C.
  • vasoconstrictor substances to the skin of patients can be used to induce vasoconstriction in the skin to prevent or ameliorate hypothermia.
  • Application of the vasoconstrictor make take place shortly prior to the start of surgery, e.g. within 30-60 minutes of the commencement of surgery, thereby providing prophylaxis of hypothermia; or it may be conducted during or after surgery to mitigate or ameliorate the hypothermia condition.
  • Topical application of the vasoconstrictor to the skin concentrates the vasoconstrictor effects in the skin, and minimizes systemic effects of the vasoconstrictor.
  • application of one or more vasoconstrictors to the skin may be accompanied by application of heat from a source external to the patient.
  • vasoconstrictor may be needed in order to induce and maintain a high degree vasoconstriction (evidenced in visible skin blanching) for extended periods of time.
  • a combination of vasoconstrictors is used in order to obtain extended elevated vasoconstrictor effects.
  • some topical vasoconstrictors such as epinephrine, initial act quickly (within about 20 minutes of application), but their activity diminishes significantly after 3 hours, whereas topical corticosteroids only begin to have significant vasoconstrictor effect about 7 hours after application, with lasting effects up to about 17 hours after application.
  • Other vasoconstrictors, such as phenylephrine when applied dermally, show intermediate periods of activity when applied topically, beginning to show their vasoconstricting effects after about 3 hours after application.
  • the use of different combinations of vasoconstrictors, applied separately or in single formulation, can be conceived to address need of treatment for different lengths of time.
  • prevention or amelioration or minimization of hypothermia according to embodiments of the present invention can be fitted to different time scales depending on the planned duration of anesthesia associated with different known surgical operations.
  • Diosmin prolongs the vasoconstrictor effect of noradrenaline on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and stasis.
  • a combination of vasoconstrictor agent and diosmin is provided in accordance with some embodiments of the invention.
  • vasodilator is preferably of a nitric-oxide donor type (e.g., nitroglycerine and derivatives) which primarily dilate internal, large blood vessels, and has relatively marginal effect on skin capillaries.
  • a nitric-oxide donor type e.g., nitroglycerine and derivatives
  • the one or more vasoconstrictors are selective alpha agonist substances, such as phenylephrine or methoxamine.
  • Antiseptic combination In the context of surgical operations, there is value to have the patient body skin surface as sterile as possible. Disinfection by topical alcohol swabs is common in patient preparation for surgery.
  • the composition containing one or more vasoconstrictors further comprises a disinfecting agent, as known in the art.
  • topical dermal administration of vasoconstrictors is utilized; this minimizes systemic effects of the vasoconstrictors.
  • Absorption through body outer surface skin is known to be less than via mucous membranes, e.g. via rectal, nasal or eye tissues.
  • active vasoconstrictor concentration in the topical formulations will often need to be higher than 1%.
  • the inclusion of a transdermal carrier and/or a skin penetration enhancer in such formulations may enable the concentration of the vasoconstrictors in the formulations to be reduced.
  • Transdermal carriers and penetration enhancers known to those skilled in the art include polymethacrylic acid (PMA), carbopol, polyethylene glycol 8000 (PEG), propylene glycol (PG), water, alcohol, acetone, caprylic acid, caproic acid, oleic acid, lauric acid, isopropyl myristate, triethanolamine, or mixtures thereof.
  • Transdermal penetration enhancers are also described, for example, in Karande et al., PNAS USA 102:4688-4693 (March 29, 2005). However, some of these may not be suitable for use on patients that have very sensitive skin or allergies.
  • non-proteinaceous carriers so as to form a liquid, particularly an aqueous liquid, or semi-solid or gel medium.
  • physiologically acceptable substances such as carbohydrates, polylactate, agaroses, dextrans, cellulose, gums, etc.
  • Synthetic peptides may find use, such as polylysine, polyarginine, etc.
  • the composition may be formulated with lipids to form liposomes or in a solid form in combination with silicones, epoxide resins, hydroxyapatite, etc.
  • the drugs and carrier will be selected to minimize any inactivating effects on the drugs.
  • compositions used in accordance with embodiments of the invention include known pharmaceutical forms utilized for topical cutaneous administration, including solutions, gels, lotions, creams, ointments, foams, mousses, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof.
  • solutions gels, lotions, creams, ointments, foams, mousses, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof.
  • the carrier can be in a wide variety of forms.
  • emulsion carriers including, but not limited to, oil-in-water, water-in-oil, water-in- oil-in- water, and oil-in- water-in-silicon emulsions, are useful herein.
  • a given component will distribute primarily into either the water or oil/silicon phase, depending on the water solubility/dispersibility of the component in the composition.
  • a safe and effective amount of carrier is from about 50% to about 99.99%.
  • the composition can contain excipients, binders, lubricants, disintegrants and the like, as is known in the art. If desired, it can also contain oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extracts, hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents; additional pharmaceutically effective components such as vitamins, hormones, amino acids; surfactants, colorants, dyes, pigments, fragrances, odor absorbers; antiseptics, preservatives, bactericides; humectants, thickeners, solvents, fillers; antioxidants; sequestering agents; sunscreens; or other known components and additives that do not unduly impair the vasoconstrictive effects of the vasoconstrictor.
  • oily materials such as various fats, oils, waxes, hydrocarbons, fatty acids, higher alcohols, ester oils, metallic soaps, animal or vegetable extract
  • compositions for topical dermal administration are described in Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., 1990, and Remington: The Science and Practice of Pharmacy, 20th Edition, edited by A. Genaro, Lippincott Williams and Wilkins, Baltimore, MD, 2000.
  • suitable oils includes mineral oils, plant oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others.
  • mineral oils such as peanut oil, sesame oil, soybean oil, safflower oil, sunflower oil, animal oils such as lanolin or perhydrosqualene, synthetic oils such as purcellin oil, silicone oils such as cyclomethicome among others.
  • Fatty alcohols, fatty acids such as stearic acid and waxes such as paraffin wax, carnauba wax or beeswax may also be used as fats.
  • the composition may also contain emulsifying agents such as glyceryl stearate, solvents such as lower alcohols including ethanol, isopropanol, and propylene glycol, hydrophilic gelling agents including carboxy vinyl polymers or acrylic copolymers, polyacrylamides, polysaccharides, lipophilic gelling agents or fatty acid metal salts among others, hydrophilic acting agents such as amino acids, sugars, starch or urea, lipophilic active agents such as retinol or tocopherol.
  • emulsifying agents such as glyceryl stearate
  • solvents such as lower alcohols including ethanol, isopropanol, and propylene glycol
  • hydrophilic gelling agents including carboxy vinyl polymers or acrylic copolymers, polyacrylamides, polysaccharides, lipophilic gelling agents or fatty acid metal salts among others
  • hydrophilic acting agents such as amino acids, sugars, starch or urea
  • lipophilic active agents such
  • the drug(s) can be employed encapsulated in liposomes or other controlled rate release compositions so as to provide for separate and distinct rates of release of the drug(s).
  • other methods of encapsulation can be employed where one or more of the active ingredients are encapsulated in a biodegradable substance, where the rate of release is related to the thickness of the biodegradable coat.
  • the active ingredients used in accordance with embodiments of this invention may be uniformly dispersed in a physiologically acceptable medium, particularly aqueous, such as saline, phosphate buffered saline, distilled water, etc.
  • a physiologically acceptable medium particularly aqueous, such as saline, phosphate buffered saline, distilled water, etc.
  • the aqueous medium will be sufficient to provide for an amorphous dispersion, usually a solution, capable of flowing under mild pressure.
  • a number of minor components may also be included for a variety of purposes. These agents will for the most part impart properties which protect the stability of the composition, control the pH, or the like.
  • Illustrative agents include phosphate or acetate buffers, methyl or propyl paraben, polyethylene glycols, etc. These agents generally will be present in less than about 2 weight percent of the total composition, usually less than about 1 weight percent, and individually may vary from about 0.001 weight percent to about 1 weight percent.
  • each component may be dispensed at an appropriate concentration into a separate container for mixing just prior to administration.
  • Those components which are stable together may be dispensed together into a single container for mixture with one or more reagents containing those additional ingredients found to promote instability or to form undesirable complexes.
  • a device or kit containing separate components may be prepared which facilitates easy formulation prior to administration.
  • each separate component is formulated so that the therapeutically effective concentration of each agent is achieved when all the separate components in the kit are admixed.
  • Combination with glove/sock peripheral warming devices The use of external warming devices for selectively warming the palms and/or the feet of human subjects is particularly effective for warming of core body.
  • a glove shaped and/or sock shaped warming pad optionally formed to be fitted over human hands and/or feet, respectively, may be utilized in conjunction with the dermal application of one or more vasoconstrictors.
  • Such pads may contain heated gels or liquids or heat radiation sources as know in the art (e.g. warming pads, warming covers, warming bottles, and radiators). The control of such external heat sources is known in the art.
  • the at least one vasoconstrictor is applied topically to significant skin areas excluding the hands and/or feet, while the warming glove and sock devices are fitted and activated on the hands and/or feet respectively.
  • the graphs in Fig. 1 summarize the results of experiments conducted on rats. Although there are differences between the thermoregulatory system of rats and humans, the tails and feet pads of rats function as thermoregulatory organs in a similar fashion to human skin. The rat tail skin and feet pads are exposed and not covered by fur. By controlling the blood flow to the tail skin and feet pads, the rat controls some of its heat dissipation to the environment. Only about 30% of the rat heat loss is regulated by the tail - much less than the role of the skin in humans.
  • CBT Core body temperature
  • tail skin temperature of the rats was measured using a thermocouple- based digital thermometer with 0.1 0 C sensitivity.
  • Group C the control group, was given a topical cream containing only base cream (similar to DermabaseTM oil-in- water emulsion base, Paddock Laboratories, Inc., Minneapolis, MN) with 10 wt. % penetration enhancer (propylene glycol), but no active vasoconstrictor.
  • base cream similar to DermabaseTM oil-in- water emulsion base, Paddock Laboratories, Inc., Minneapolis, MN
  • 10 wt. % penetration enhancer propylene glycol
  • the cream for test group A the cream was identical to that used for the control group, except it contained 6 wt. % epinephrine, a vasoconstrictor.
  • the cream for test group B was the same as that for group A, except that the cream contained 20 wt.% penetration enhancer.
  • Plot lines A and C in Fig. IA show no significant difference in CBT between groups A and C for the first 40 minutes of the experiment, but thereafter show a full one degree difference is maintained between the CBT of the two groups through the remainder of the experiment.
  • Fig. IB already 20 minutes into the experiment it was observed that the temperature of the tail was higher in the control group than in group A, due to decreased blood flow to the skin of the tails of the rats in group A due to vasoconstriction in the tail skin in this group.
  • test group (B) two changes were made to the experimental procedure.
  • the concentration of penetration enhancer (propylene glycol) in the cream was doubled to 20 wt.%.
  • test group B Third, there is a rapid fall-off the test group B temperature after 2 h. These results seem to indicate that the increased level of penetration enhancer caused a rapid discharge and absorption of the vasoconstrictor. In contrast, the lower level of penetration enhancer in test group A led to slower release of the vasoconstrictor, giving rise to longer and more stable duration of vasoconstrictor activity in the skin.
  • thermometer used was good for rectal measurements but less fitting for skin measurements than the thermometer used in Example 1 ; hence, while the core temperature measurements are precise, the tail temperature measurements should be taken as indicative of relative effects but not absolute temperature.
  • the test cream composition was 10%
  • Norepinephrine vasoactive substance 10% penetration enhancer (propylene glycol), and 80% conventional base cream.
  • Norepinephrine pronounced vasoconstrictor action started about 80 min after the first application of cream, which is slower than the 20-30 min response time of the 6% Epinephrine cream used in Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L’invention concerne l’utilisation dermique topique de substances vasoconstrictrices qui permettent de réguler la température du corps pour traiter, prévenir ou retarder l’apparition d’une hypothermie induite par une anesthésie. L’invention concerne également des kits contenant des matériaux appropriés et des instructions, ainsi que  d’autres modes de réalisation.
PCT/US2009/066124 2008-06-30 2009-11-30 Application dermique de vasoconstricteurs WO2010063030A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP09829849A EP2376073A2 (fr) 2008-11-30 2009-11-30 Application dermique de vasoconstricteurs
CN2009801558027A CN102300566A (zh) 2008-11-30 2009-11-30 血管收缩剂的皮肤应用
US12/982,117 US20110144209A1 (en) 2008-06-30 2010-12-30 Use of vasoconstrictors
US13/118,563 US20120095104A1 (en) 2008-11-30 2011-05-30 Use of vasoconstrictors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11861208P 2008-11-30 2008-11-30
US61/118,612 2008-11-30
ILPCT/IL2009/000652 2009-06-30
PCT/IL2009/000652 WO2010001391A1 (fr) 2008-06-30 2009-06-30 Application dermique de vasoconstricteurs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000652 Continuation-In-Part WO2010001391A1 (fr) 2008-06-30 2009-06-30 Application dermique de vasoconstricteurs

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/IL2009/000652 Continuation-In-Part WO2010001391A1 (fr) 2008-06-30 2009-06-30 Application dermique de vasoconstricteurs
US12/982,117 Continuation-In-Part US20110144209A1 (en) 2008-06-30 2010-12-30 Use of vasoconstrictors

Publications (2)

Publication Number Publication Date
WO2010063030A2 true WO2010063030A2 (fr) 2010-06-03
WO2010063030A3 WO2010063030A3 (fr) 2011-04-21

Family

ID=42226391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/066124 WO2010063030A2 (fr) 2008-06-30 2009-11-30 Application dermique de vasoconstricteurs

Country Status (3)

Country Link
EP (1) EP2376073A2 (fr)
CN (1) CN102300566A (fr)
WO (1) WO2010063030A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031792A3 (fr) * 2012-08-21 2014-04-10 Sage Therapeutics Procédés de traitement de l'épilepsie ou d'un état de mal épileptique
WO2018123982A1 (fr) * 2016-12-26 2018-07-05 久光製薬株式会社 Dispositif à micro-aiguille
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
US10322139B2 (en) 2012-01-23 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US10772871B2 (en) 2013-10-07 2020-09-15 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
US10874642B2 (en) 2013-10-07 2020-12-29 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12233156B2 (en) 2018-06-26 2025-02-25 Hisamitsu Pharmaceutical Co., Inc. Microneedle device and method for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALFONSI P.: 'Postanaesthetic shivering. Epidemiology, pathophysiology, and approaches to prevention and management' MINERVA ANESTESIOLOGICA vol. 69, no. 5, May 2003, pages 438 - 442 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US11426417B2 (en) 2012-01-23 2022-08-30 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
US10322139B2 (en) 2012-01-23 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating CNS disorders
WO2014031792A3 (fr) * 2012-08-21 2014-04-10 Sage Therapeutics Procédés de traitement de l'épilepsie ou d'un état de mal épileptique
US12048706B2 (en) 2012-08-21 2024-07-30 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
US10251894B2 (en) 2012-11-30 2019-04-09 The Regents Of The University Of California Anticonvulsant activity of steroids
US10772871B2 (en) 2013-10-07 2020-09-15 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
US10874642B2 (en) 2013-10-07 2020-12-29 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US10987342B2 (en) 2013-10-07 2021-04-27 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
US12083131B2 (en) 2014-09-08 2024-09-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10940156B2 (en) 2016-03-08 2021-03-09 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11554125B2 (en) 2016-03-08 2023-01-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018123982A1 (fr) * 2016-12-26 2018-07-05 久光製薬株式会社 Dispositif à micro-aiguille
US12233156B2 (en) 2018-06-26 2025-02-25 Hisamitsu Pharmaceutical Co., Inc. Microneedle device and method for producing the same

Also Published As

Publication number Publication date
CN102300566A (zh) 2011-12-28
WO2010063030A3 (fr) 2011-04-21
EP2376073A2 (fr) 2011-10-19

Similar Documents

Publication Publication Date Title
US20110144209A1 (en) Use of vasoconstrictors
WO2010063030A2 (fr) Application dermique de vasoconstricteurs
CN103316078B (zh) 一种舒眠降温贴剂及其制备方法
US20120095104A1 (en) Use of vasoconstrictors
CN104546802B (zh) 治疗风湿性关节炎的自发热中药敷贴及其制备方法
CN106474444A (zh) 一种外用中药药包配方、药包及其使用方法
CN100388932C (zh) 一种治疗足癣外用药物的制作方法
CN106726101A (zh) 一种蜡疗用中药蜡块及其制备方法
CN112057585A (zh) 含有多种精油治疗颈肩腰腿痛的贴剂配方及其制备方法
CN110101832B (zh) 一种桢楠中药组合物及其制备方法
CN103520690B (zh) 一种舒筋通络降压浴足粉
CN110507794A (zh) 一种远红外热敷疗法用中药包
CN114404480A (zh) 一种筋骨通关贴及其制作方法
CN107468594A (zh) 一种肩颈疏通的植物按摩精华及制备方法
CN107184652A (zh) 一种温旋艾灸配方
CN1136797C (zh) 健步鞋垫及其生产方法
CN105687797A (zh) 一种用于治疗烧烫伤的药物制剂及其用途
CN113058018A (zh) 一种温经散寒、活血止痛的药膏
CN105213677A (zh) 一种用于表面麻醉的中药膜及其制备方法
CN206964718U (zh) 一种蜡疗用中药蜡块
CN103656139B (zh) 外用膏药及制备方法
KR101983693B1 (ko) 피부온도 감응형 기능성 하이드로겔 조성물을 이용한 발바닥 피로완화와 각질 개선용 패치 및 그 제조방법
CN102283541A (zh) 一种药草保健枕头
CN115054652B (zh) 一种具有抗汗匀控功能的三伏贴及其制备方法
US20210196781A1 (en) Skin balm

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980155802.7

Country of ref document: CN

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009829849

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09829849

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载